ATRCAtriCure, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.
Priced for ~10% a year FCF growth. The price demands less than its three-year revenue growth of 16% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ATRC's price assumes
AtriCure, Inc. trades at 266× earnings against 39.6× for the median Medical Instruments & Supplies name, more expensive than its own group.
Trailing P/E · Medical Instruments & Supplies median 39.6 · 6.70× the median: the market pays up for this one
- Price / sales
- 2.50
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 3.7%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
- Growth the price implies
- +9.5%
Growth the price implies · The price pays for +9.5% free cash flow growth a year for a decade; revenue has grown +16% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 2.76
- EV / EBIToperating margin 2.3%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.31
- Healthcare median P/E509 names
- 26.2
- Medical Instruments & Supplies median P/E33 names
- 39.6
- Free cash flow, trailing twelve months
- $53M
- Market capitalisation
- $1.42B
- 3-year revenue growth
- +16%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #17 of 21 by RyuScore